CareLit · DOI-Nachweis · Geburtshilfe und Frauenheilkunde
Prospective evaluation of QTc-interval prolongation in patients with advanced ovarian cancer after treatment with carboplatin, paclitaxel and bevacizumab
DOI 10.1055/s-0036-1593012
Bibliografische Angaben
Nachweis in CareLit
Autor:innenJ Puppe, D van Ooyen, J Neise, F Thangarajah, C Eichler, C Fridrich, B Morgenstern, R Pfister, P Mallmann, M Wirtz, G Michels
ZeitschriftGeburtshilfe und Frauenheilkunde
Ausgabe10/2016
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Angiogenesis has become an important target for antineoplastic therapy of advanced ovarian cancer and the monoclonal antibody bevacizumab directed against the vascular endothelial growth factor (VEGF) is broadly used in the clinic. This drug is associated with cardiovacular toxicities such as hypertension. However, the effect of bevacizumab on life-threatening electrocardiographic alterations including c…
Zitieren
Zitierempfehlung
J Puppe, D van Ooyen, J Neise, F Thangarajah, C Eichler, C Fridrich, B Morgenstern, R Pfister, P Mallmann, M Wirtz, G Michels (2016) Prospective evaluation of QTc-interval prolongation in patients with advanced ovarian cancer after treatment with carboplatin, paclitaxel and bevacizumab. Geburtshilfe und Frauenheilkunde (10). https://doi.org/10.1055/s-0036-1593012
Mit CareLit weiterarbeiten